by Stevan Looney
I am a civil trial and appellate
attorney in New Mexico, with experience litigating complex matters. My
prior essay for DailyClout.io regarding the Pfizer WarRoom Document
Review — for which I volunteer as one of 250 attorneys — argued that the
documents clearly show evidence of fraud on the part of Pfizer. The
latest tranche of documents, released on April 1, 2022, show an equally
dramatic revelation: Pfizer knew by February of 2021, that there were had been ‘a large number of adverse events’ in the three months prior
Pfizer also realized that these adverse
events were so abundant — and they expected so many more in the months
to come — that they advised the FDA that they would hire 2400 additional
staffers to deal with the paperwork and data processing they expected
due to the anticipated volume of adverse events!
I reviewed the April 1, 2022, tranche
of Pfizer documents the FDA produced pursuant to a federal court order.
A document produced on November 17, 2021, was also produced as
“reissued” on April 1, 2022. At first glance they appear identical, but
they are not. Importantly, information redacted (deleted) from the
document produced in the March 2022 production, was included in the
April 1, 2022, production. This information is quite telling and some
conclusions can be drawn.
The document produced on November 17, 2021, is titled “5.3.6 postmarketing experience.pdf
” (November 17, 2021 (984 KB)). That same document in the April 1, 2022, production is titled “reissue_5.3.6 postmarketing experience.pdf
(April 1, 2022 (958 KB)). The word “reissue” is absent in the November
2021 version. That made me curious, so I did a comparison of the two
documents. Here is what one will find on page 6. (The “Bates” number in
both documents in the bottom, right-hand corner is
The lengthy paragraph on page 6 of
the November 2021 document concerns adverse events reports received by
Pfizer as of February 28, 2021. The third sentence of that paragraph in
both documents reads: “Due to the large number of spontaneous adverse
events reports received for the product [i.e., BNT162b2], the MAH
[Marketing Authorization Holder] has prioritized the processing of
serious cases, in order to meet expedited regulatory reporting timelines
and ensure these reports are available for signal detection and
This paragraph ends: “Pfizer has also
taken a [sic] multiple actions to help alleviate the large increase of
adverse event reports.” Think about that sentence.
significant technology enhancements, and process and workflow solutions,
as well as increasing the number of data entry and case processing
colleagues. To date, Pfizer has onboarded approximately 600 additional full-time employees (FTEs). More are joining each month with an expected total of more than 1,800 additional resources by the end of June 2021 [emphasis added].”
Also on page 6, under the heading “3.
RESULTS”, at “3.1.1 General Overview”, Pfizer discloses in the document
produced on April 1, 2022, what it redacted from the same document
produced in November of 2021. What Pfizer had produced in April 2022 to
take the place of the redacted document in November 2021 document was
the fact that for the three-month period beginning December 1, 2020, to
February 28, 2021, Pfizer shipped “approximately 126,212,580 [emphasis added] doses of [the FDA emergency use authorized] BNT162b2″ worldwide.
The 126,212,580 figure is redacted in the document produced in
November 2021 but is included in the “reissue” document of April 1,
Likewise, the new, full-time 600 and
1,800 employees, amounting to a total of 2,400 full-time employees,
hired to deal with all the anticipated adverse events, are included in
the document produced on April 1, 2022, but had been redacted from the
same document the FDA had produced in November of 2021. Why the
foregoing data were redacted, but then disclosed, we do not know, yet.
We do know that the redacted information is damning. What did we learn
by comparing the two documents?
First, between December 1, 2020 and
February 28, 2021, a period of three months, “a large number of
spontaneous adverse events reports” were made to Pfizer regarding the
administration to humans of the BNT162b2 “vaccine” for which the FDA had
provided emergency use authorization (EUA).
Second, by February 28, 2021, (the
date of the document) Pfizer knew that by June of 2021 it would hire at
least an additional 2,400 full-time employees to process the adverse
events reports Pfizer was receiving. (Appendix 1 to these documents is a
list of 1,290 adverse events of special interest (AESI) received in
connection with the BNT162b2 “product.” Based upon my research to date, I
have found no evidence that these AESI were disclosed publicly prior to
November of 2021.)
Lastly, and incredibly, despite
having this information, on August 23, 2021, the FDA granted continued
EUA status for the BNT162b2 “vaccine” and also approved
Bio-N-Tech/Pfizer’s product known as COMIRNATY. Notably, according to
the FDA, both the EUA BNT162b2 and the “approved” COMIRNATY are
identical and interchangeable products. Thus, it is reasonable to
conclude that COMIRNATY also causes “a large number of spontaneous
adverse events,” including the adverse events and AESI listed in
Appendix 1 to these documents.In sum, Pfizer did not only apparently commit fraud, but they
also compounded the fraud by hiring 2,400 full-time employees to deal
with the flood of adverse events that they expected – and yet they told
no one about this publicly.
I will continue to issue analyses of these historic documents.
Article Source: https://dailyclout.io/how-pfizer-covered-up-anticipated-adverse-events/
Mr. Looney is a civil trial and
appellate attorney with 42 years of experience, concentrating on complex
matters. Mr. Looney is licensed in New Mexico and practices in all its
courts, as well as the United States District Court for the District of
New Mexico, the Tenth Circuit Court of Appeals, the US Tax Court and
the US Supreme Court. Mr. Looney served in the U.S. Army as an
infantryman from 1970-1972, assigned to the 82nd Arbrn. Div.